Type 1 diabetes: Pathogenesis and prevention

CMAJ. Canadian Medical Association Journal

Volumn 175, Issue 2, 2006, Pages 165-170

  Gillespie, Kathleen M ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLOSPORIN; DACLIZUMAB; IMMUNOMODULATING AGENT; INSULIN; MONOCLONAL ANTIBODY CD3; PANCREAS ISLET CELL ANTIBODY; RAPAMYCIN; TACROLIMUS; VITAMIN D;

AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CHRONIC DISEASE; ENVIRONMENTAL FACTOR; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HAPLOTYPE; HEREDITY; HLA SYSTEM; HUMAN; HYGIENE; IMMUNOASSAY; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL RESEARCH; MORTALITY; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS TRANSPLANTATION; PROTEIN INDUCTION; REVIEW; RISK FACTOR; RUBELLA; SCREENING; STEM CELL; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; ENVIRONMENT; GENETICS; IMMUNOLOGY;

DIABETES MELLITUS, TYPE 1; ENVIRONMENT; HUMANS; RISK FACTORS;

EID: 33746207753     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060244     Document Type: Review

References (77)

1. Foulis AK, McGill M, Farquharson MA. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man - macrophages, lymphocytes, and interferon-gamma containing cells. J Pathol 1991;165:97-103.
2. EURODIAB ACE Study Group. Variation and trends in incidence of childhood diabetes in Europe. Lancet 2000;355:873-6.
3. Onkamo P, Vaananen S, Karvonen M, et al. Worldwide increase in incidence of type 1 diabetes - the analysis of the data on published incidence trends. Diabetologia 1999;42:1395-403.
4. Cudworth AG, Woodrow JC. HLA system and diabetes mellitus. Diabetes 1975;24:345-9.
5. Nerup J, Platz P, Andersen OO, et al. HLA antigens and diabetes mellitus. Lancet 1974;2:864-6.
6. Risch N. Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet 1987;40:1-14.
7. Todd JA. Genetic analysis of type 1 diabetes using whole genome approaches. Proc Natl Acad Sci U S A 1995;92:8560-6.
8. Devendra D, Eisenbarth GS. Immunologic endocrine disorders. J Allergy Clin Immunol 2003;111:S624-36.
9. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 2004;350:2068-79.
10. Caillat-Zucman S, Garchon HJ, Timsit J, et al. Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest 1992;90:2242-50.
11. Gillespie KM, Gale EAM, Bingley PJ. High familial risk and genetic susceptibility in early onset childhood diabetes. Diabetes 2002;51:210-4.
12. Bell GI, Horita S, Karam JH. A polymorphic locus near the insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984;33:176-83.
13. Bennett ST, Lucassen AM, Gough SCL, et al. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet 1995;9:284-92.
14. Vafiadis P, Bennett ST, Todd JA, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997;15:289-92.
15. Pugliese A, Zeller M, Fernandez A Jr, et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997;15:293-7.
16. Mein CA, Esposito L, Dunn MG, et al. A search for type 1 diabetes susceptibility genes in families from the United Kingdom. Nat Genet 1998;19:297-300.
17. Concannon P, Gogolin-Ewens KJ, Hinds DA, et al. A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. Nat Genet 1998;19:292-6.
18. Cox NJ, Wapelhorst B, Morrison VA, et al. Seven regions of the genome show evidence of linkage to type 1 diabetes in a consensus analysis of 767 multiplex families. Am J Hum Genet 2001;69:820-30.
19. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506-11.
20. Atabani SF, Thio CL, Divanovic S, et al. Association of CTLA4 polymorphism with regulatory T cell frequency. Eur J Immunol 2005;35:2157-62.
21. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type 1 diabetes. Nat Genet 2004;36:337-8.
22. Smyth D, Cooper JD, Collins JE, et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004;53:3020-3.
23. Gregersen PK. Gaining insight into PTPN22 and autoimmunity. Nat Genet 2005;37:1300-2.
24. Becker KG. Comparative genetics of type 1 diabetes and autoimmune disease: Common loci, common pathways? Diabetes 1999;48:1353-8.
25. Fronczak CM, Baron AE, Chase HP, et al. In utero dietary exposures and risk of islet autoimmunity in children. Diabetes Care 2003;26:3237-42.
26. Hyppönen E, Läärä E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth cohort study. Lancet 2001;358:1500-3.
27. Mathieu C, Badenhoop K. Vitamin D and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab 2005;16:261-6.
28. Mahomed K, Gulmezoglu AM. Vitamin D supplementation in pregnancy [review]. Cochrane Database Syst Rev 2000;(2):CD000228.
29. Nejentsev S, Cooper JD, Godfrey L, et al. Analysis of the vitamin D receptor gene sequence variants in type 1 diabetes. Diabetes 2004;53:2709-12.
30. Pani MA, Knapp M, Donner H, et al. Vitamin D receptor allele combinations influence genetic susceptibility to type 1 diabetes in Germans. Diabetes 2000;49:504-7.
31. Nejentsev S, Guja C, McCormack R, et al. Association of intercellular adhesion molecule-1 gene with type 1 diabetes. Lancet 2003;362:1723-4.
32. Pundziute-Lycka A, Dahlquist G, Nystrom L, et al. Incidence of type 1 diabetes has not increased but shifted to a younger age at diagnosis in the 34 years group in Sweden 1983-1998. Diabetologia 2002;45:783-91.
33. Weets I, De Leeuw IH, Du Caju MV, et al. The incidence of type 1 diabetes in the age group 0-39 years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation. Diabetes Care 2002;25:840-6.
34. Hermann R, Knip M, Veijola R, et al. Temporal changes in the frequencies of HLA genotypes in patients with type 1 diabetes - Indication of an increased environmental pressure? Diabetologia 2003;46:420-5.
35. Gillespie KM, Bain SC, Barnett AH, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004;364:1699-700.
36. Hyoty H. Enterovirus infections and type 1 diabetes. Ann Med 2002;34:138-47.
37. Honeyman MC, Coulson BS, Stone NL, et al. Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes 2000;49:1319-24.
38. Ginsberg-Fellner F, Witt ME, Fedun B, et al. Diabetes mellitus and autoimmunity in patients with the congenital rubella syndrome. Rev Infect Dis 1985;7(Suppl 1):S170-6.
39. Peltola H, Davidkin I, Paunio M, et al. Mumps and rubella eliminated from Finland. JAMA 2000;284:2643-7.
40. Viskari H, Ludvigsson J, Uibo R, et al. Relationship between the incidence of type 1 diabetes and maternal enterovirus antibodies: time trends and geographical variation. Diabetologia 2005;48:1280-7.
41. Gale EA. A missing link in the hygiene hypothesis? Diabetologia 2002;45:588-94.
42. Bach JF. Infections and autoimmune diseases. J Autoimmun 2005;25:74-80.
43. Baekkeskov S, Warnock G, Christie M, et al. Revelation of specificity of 64K autoantibodies in IDDM serums by high-resolution 2-D gel electrophoresis. Unambiguous identification of 64K target antigen. Diabetes 1989;38:1133-41.
44. Lan MS, Wasserfall C, Maclaren NK et al. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A. 1996 25;93:6367-70.
45. Palmer JP. Insulin autoantibodies: their role in the pathogenesis of IDDM. Diabetes Metab Rev 1987;3:1005-15.
46. Verge CF, Stenger D, Bonifacio E, et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 1998;47:1857-66.
47. Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003;52:1128-36.
48. Vandewalle CL, Decraene T, Schuit FC, et al. Insulin autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA DQA1*0301-DQB1*0302 haplotype at clinical type 1 (insulin-dependent) diabetes mellitus before age 10 years, but not at onset between age 10 and 40 years. The Belgian Diabetes Registry. Diabetologia 1993;36:1155-62.
49. Gorus FK, Goubert P, Semakula C, et al. IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. The Belgian Diabetes Registry. Diabetologia 1997;40:95-9.
50. Decochez K, Tits J, Coolens JL. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. Diabetes Care 2000;23:838-44.
51. Ziegler A.G., Hummel M., Schenker M., et al. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999;48:460-8.
52. Bingley PJ, Williams AJK, Gale EAM. Optimized autoantibody-based risk assessment in family members. Diabetes Care 1999;22:1796-801.
53. Bingley PJ, Bonifacio E, Williams AJK, et al. Prediction of IDDM in the general population. Strategies based on combinations of autoantibody markers. Diabetes 1997;46:1701-10.
54. Decochez K, Truyen I, van der Auwera B, et al. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines populations at high risk of developing type 1 diabetes. Diabetologia 2005;48:687-94.
55. Achenbach P, Warncke K, Reiter J, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004;53:384-9.
56. Van der Auwera BJ, Schuit FC, Weets I, et al. Relative and absolute HLA-DQA1-DQB1 linked risk for developing type 1 diabetes before 40 years of age in the Belgian population: implications for future prevention studies. Hum Immunol 2002;63:40-50.
57. Nejentsev S, Sjoroos M, Soukka T, et al. Population-based genetic screening for the estimation of type 1 diabetes mellitus risk in Finland: selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci. Diabet Med 1999;16:985-92.
58. Gale EA, Bingley PJ, Emmett CL, et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925-31.
59. Diabetes Prevention Trial-Type 1 Diabetes Study Group: Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-91.
60. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2005;28:1068-76.
61. Kent SC, Chen Y, Bregoli L, et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005;435:224-8.
62. Nakayama M, Abiru N, Moriyama H, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005;435:220-3.
63. Feutren G, Papoz L, Assan R, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986;2:119-24.
64. Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988;37:1574-82.
65. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-9.
66. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl Med 2005;352:2598-608.
67. Bisikirska B, Colgan J, Luban J, et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005;115:2904-13.
68. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-8.
69. DiPaolo RJ, Glass DD, Bijwaard KE, et al. CD4+CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J Immunol 2005;175:7135-42.
70. Burke GW, Ciancio G, Sollinger HW. Advances in pancreas transplantation. Transplantation 2004 15;77:S62-7.
71. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant 2005;19:433-55.
72. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-8.
73. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005;54:2060-9.
74. Ricordi C. Islet transplantation: a brave new world. Diabetes 2003;52:1595-603.
75. Meier JJ, Bhushan A, Butler AE. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: Indirect evidence for islet regeneration? Diabetologia 2005;48:2221-8.
76. Seaberg RM, Smukler SR, Kieffer TJ. Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. Nat Biotechnol 2004:22:115-24.
77. Dor Y, Brown J, Martinez OI. Adult pancreatic beat-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004;429:41-6.